This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, W. Articles by Olumi, A. F. Search for Related Content PubMed PubMed Citation Articles by Li, W. Articles by Olumi, A. F.

MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L)

Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Aria F. Olumi, Department of Urology, Massachusetts General Hospital, Harvard Medical School, Yawkey Building, Suite 7E, 55 Fruit St., Boston, MA 02114. Phone: 617-643-0237; E-mail: aolumi{at}partners.org.

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it induces apoptosis in cancer cells but not in normal cells. Unfortunately, some cancer cells develop resistance to TRAIL-induced apoptosis. Therefore, it is clinically relevant to determine the molecular mechanisms that differentiate between TRAIL-sensitive and TRAIL-resistant tumors. Previously, we have shown that the antiapoptotic molecule cellular-FLICE-inhibitory protein long isoform [c-FLIP(L)] is necessary and sufficient to maintain resistance to TRAIL-induced apoptosis. We have found that c-FLIP(L) is transcriptionally regulated by the activator protein-1 (AP-1) family member protein c-Fos. Here, we report that MG-132, a small-molecule inhibitor of the proteasome, sensitizes TRAIL-resistant prostate cancer cells by inducing c-Fos and repressing c-FLIP(L). c-Fos, which is activated by MG-132, negatively regulates c-FLIP(L) by direct binding to the putative promoter region of the c-FLIP(L) gene. In addition to activating c-Fos, MG-132 activates another AP-1 family member, c-Jun. We show that c-Fos heterodimerizes with c-Jun to repress transcription of c-FLIP(L). Therefore, MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [Cancer Res 2007;67(5):2247–55]

This article has been cited by other articles:

				C. Wilson, T. Wilson, P. G. Johnston, D. B. Longley, and D. J.J. Waugh Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells Mol. Cancer Ther., September 1, 2008; 7(9): 2649 - 2661. [Abstract] [Full Text] [PDF]

				N. Ueffing, M. Schuster, E. Keil, K. Schulze-Osthoff, and I. Schmitz Up-regulation of c-FLIPshort by NFAT contributes to apoptosis resistance of short-term activated T cells Blood, August 1, 2008; 112(3): 690 - 698. [Abstract] [Full Text] [PDF]

				X. Zhang, W. Li, and A. F. Olumi Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptosis in Prostate Cancer Cells Clin. Cancer Res., December 1, 2007; 13(23): 7181 - 7190. [Abstract] [Full Text] [PDF]

				X. Zhang, L. Zhang, H. Yang, X. Huang, H. Otu, T. A. Libermann, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi c-Fos as a Proapoptotic Agent in TRAIL-Induced Apoptosis in Prostate Cancer Cells Cancer Res., October 1, 2007; 67(19): 9425 - 9434. [Abstract] [Full Text] [PDF]

				M. Jagla, M. Feve, P. Kessler, G. Lapouge, E. Erdmann, S. Serra, J.-P. Bergerat, and J. Ceraline A Splicing Variant of the Androgen Receptor Detected in a Metastatic Prostate Cancer Exhibits Exclusively Cytoplasmic Actions Endocrinology, September 1, 2007; 148(9): 4334 - 4343. [Abstract] [Full Text] [PDF]